Innovation Pharmaceuticals Inc. · OTC:IPIX
Innovation Pharmaceuticals — Investor Presentation (September 2022)
14 slides from Innovation Pharmaceuticals's investor presentation, September 2022
Slide 1: Corporate Overview
Corporate Overview September 2022 301 Edgewater Place, Ste 100, Wakefield, MA www.ipharminc.com Ticker: IPIX
Slide 2: Safe Harbor: Forward-Looking Statements
Safe Harbor Forward-Looking Statements This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including, without limitation, statements concerning future product development plans, including with respe
Slide 3: Senior Management and Key Advisors
Innovation Pharmaceuticals Senior Management and Key Advisors LEO EHRLICH • >25 years of executive leadership experience in building and managing emerging growth companies Co-Founder, CEO, CFO, Board Chairman Expertise • Multiple C-suite roles at private and public companies JANE HARNESS, MS, MP • >
Slide 4: Diversified Clinical Pipeline, Targeting Multiple Indications
Innovation Pharmaceuticals Diversified Clinical Pipeline, Targeting Multiple Indications Innovation Pharmaceuticals, a publicly-traded biopharmaceutical company established in 2007 (ticker: IPIX), owns intellectual property and development rights to Brilacidin, a defensin-mimetic drug candidate with
Slide 5: Brilacidin: A Host Defense Protein (HDP) Mimetic
Brilacidin: A Host Defense Protein (HDP) Mimetic Fully Synthetic, Non-Peptidic, Small Molecule Design Approach Mimics HDP Structure and Activity Biological activities of defensins depend on an amphiphilic helix • Cationic (charged) • Hydrophobic Brilacidin (PMX-30063) is the result of biocomputation
Slide 6: Brilacidin: Background on Host Defense Proteins (HDPs)
Brilacidin: Background on Host Defense Proteins (HDPs) Wide Range of Therapeutic Activity Intrinsic to HDPs HDPs are Small Antimicrobial Peptides • Expressed widely in the animal kingdom • Produced in skin, mucosal surfaces, neutrophils First Line of Defense Against Foreign Invasion (Swiss Army Knif
Slide 7: Brilacidin for Oral Mucositis: Phase 2 Trial Results
Brilacidin for Oral Mucositis: Phase 2 Trial Results Reduced Incidence of Severe Oral Mucositis (SOM); Delayed Time to Onset of SOM Brilacidin oral rinse demonstrated strongest Kaplan-Meier Curves for Time to Onset of SOM, therapeutic benefit in Head and Neck Cancer patients 21-day Cisplatin Schedul
Slide 8: Brilacidin for COVID-19: Phase 2 Trial Results
Brilacidin for COVID-19: Phase 2 Trial Results Primary Endpoint not Met but Beneficial Treatment Effects Observed Intravenous, Placebo-Controlled; 3- and 5-Day Dosing; Moderate-to-Severe COVID-19 (N=120 Subjects) Summary of Results • Patient subgroups with the highest baseline values for key inflamm
Slide 9: Brilacidin: Dual-Acting Antiviral MOA
Brilacidin: Dual-Acting Antiviral MOA Findings from Academic Research Collaborations: Targets Virus and Host; an Entry/Early Entry Inhibitor Brilacidin Disrupts Viral Integrity and Blocks Viral Entry Less Likely to Drive Resistance and Give Rise to Variants Time of Addition Experiments HSPGs: Hepara
Slide 10: Brilacidin for IBD (UP/UPS): Phase 2 Trial Results
Brilacidin for IBD (UP/UPS*): Phase 2 Trial Results Rectal Enema Formulation; Demonstrated Clinical Remission, Supported by Endoscopic Improvement Clinical Remission in Majority of Patients at Week 6 (Day 42) Colonic tissue biopsies at Week 6 (D42) demonstrate reduction in inflammatory biomarkers Si
Slide 11: Brilacidin for ABSSSI: Phase 2b Trial Results
Brilacidin for ABSSSI: Phase 2b Trial Results Single-Dose Brilacidin Comparable to 7-Day Regimen of Daptomycin Brilacidin IV infusion demonstrated efficacy comparable to active comparator in two Current Perspectives Phase 2 studies in patients with Acute Bacterial Skin and Skin Structure Infections
Slide 12: BT BeaMedical (BeaMed): Novel Imaged Guided Surgical Laser Platform
BT BeaMedical (BeaMed): Novel Imaged Guided Surgical Laser Platform In June 2022 Company Acquired a $4m Stake in BeaMed BeaMed pursuing FDA 510(k) pathway for marketing clearance in the U.S. and the corresponding process for a CE Mark in Europe BeaMed is the inventor and developer of the StingRay La
Slide 13: Innovation Pharmaceuticals—Strategic Direction
Innovation Pharmaceuticals—Strategic Direction Clinical Pipeline • Pursue Brilacidin Partnering/Licensing Efforts • Advance Phase 3-ready Oral Rinse Brilacidin Program in Oral Mucositis (pending securing sufficient working capital) • Continue to Research Brilacidin’s Antiviral and Other Properties •
Slide 14: Innovation Pharmaceuticals
Innovation Pharmaceuticals 301 Edgewater Place, Ste 100 Wakefield, MA September 2022 www.ipharminc.com Ticker: IPIX
Innovation Pharmaceuticals — Investor Presentation (September 2022) on 6ix